Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Müschen M[au]:

Histone H3 trimethylation at lysine 36 guides m<sup>6</sup>A RNA modification co-transcriptionally. Huang H et al. Nature. (2019)

Metabolic gatekeeper function of B-lymphoid transcription factors. Chan LN et al. Nature. (2017)

Retraction. et al. J Exp Med. (2006)

Search results

Items: 1 to 50 of 150

1.

Infectious stimuli promote malignant B-cell acute lymphoblastic leukemia in the absence of AID.

Rodríguez-Hernández G, Opitz FV, Delgado P, Walter C, Álvarez-Prado ÁF, González-Herrero I, Auer F, Fischer U, Janssen S, Bartenhagen C, Raboso-Gallego J, Casado-García A, Orfao A, Blanco O, Alonso-López D, Rivas JL, Tena-Dávila SG, Müschen M, Dugas M, Criado FJG, Cenador MBG, Vicente-Dueñas C, Hauer J, Ramiro AR, Sanchez-Garcia I, Borkhardt A.

Nat Commun. 2019 Dec 5;10(1):5563. doi: 10.1038/s41467-019-13570-y.

2.

Coactivation of NF-κB and Notch signaling is sufficient to induce B cell transformation and enables B-myeloid conversion.

Xiu Y, Dong Q, Fu L, Bossler A, Tang X, Boyce B, Borcherding N, Leidinger M, Sardina JL, Xue HH, Li Q, Feldman A, Aifantis I, Boccalatte F, Wang L, Jin M, Khoury J, Wang W, Hu S, Yuan Y, Wang E, Yuan J, Janz S, Colgan J, Habelhah H, Waldschmidt T, Müschen M, Bagg A, Darbro B, Zhao C.

Blood. 2019 Oct 11. pii: blood.2019001438. doi: 10.1182/blood.2019001438. [Epub ahead of print]

PMID:
31697816
3.

Origins of the human B-cell lineage.

Müschen M.

Blood. 2019 Sep 26;134(13):998-999. doi: 10.1182/blood.2019002573. No abstract available.

4.

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.

Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, Sun H, Walter M, Wei G, Smith DL, Sun X, Fei F, Xie J, Panagopoulou TI, Chen CW, Song JY, Aldoss I, Kayembe C, Sarno L, Müschen M, Inghirami GG, Forman SJ, Kwak LW.

Sci Transl Med. 2019 Sep 25;11(511). pii: eaaw9414. doi: 10.1126/scitranslmed.aaw9414.

PMID:
31554741
5.

The CRISPR/Cas9-mediated gene deletion efficiently retards the progression of Philadelphia-positive acute lymphoblastic leukemia in a p210 BCR-ABL1T315I mutation mouse model.

Tan YT, Ye L, Xie F, Wang J, Müschen M, Chen SJ, Kan YW, Liu H.

Haematologica. 2019 Sep 19. pii: haematol.2019.229013. doi: 10.3324/haematol.2019.229013. [Epub ahead of print]

6.

Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia.

Hurtz C, Chan LN, Geng H, Ballabio E, Xiao G, Deb G, Khoury H, Chen CW, Armstrong SA, Chen J, Ernst P, Melnick A, Milne T, Müschen M.

Genes Dev. 2019 Sep 1;33(17-18):1265-1279. doi: 10.1101/gad.327593.119. Epub 2019 Aug 8.

PMID:
31395741
7.

Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.

Zhu Y, He X, Lin YC, Dong H, Zhang L, Chen X, Wang Z, Shen Y, Li M, Wang H, Sun J, Nguyen LX, Zhang H, Jiang W, Yang Y, Chen J, Müschen M, Chen CW, Konopleva MY, Sun W, Jin J, Carlesso N, Marcucci G, Luo Y, Li L.

Blood. 2019 Oct 10;134(15):1257-1268. doi: 10.1182/blood.2019002457.

PMID:
31395602
8.

Chemical choreography of germinal center B-cell migration.

Ngo VN, Müschen M.

Cell Res. 2019 Jul;29(7):514-515. doi: 10.1038/s41422-019-0170-7. No abstract available.

PMID:
31024167
9.

Metabolic gatekeepers to safeguard against autoimmunity and oncogenic B cell transformation.

Müschen M.

Nat Rev Immunol. 2019 May;19(5):337-348. doi: 10.1038/s41577-019-0154-3. Review.

PMID:
30890785
10.

Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally.

Huang H, Weng H, Zhou K, Wu T, Zhao BS, Sun M, Chen Z, Deng X, Xiao G, Auer F, Klemm L, Wu H, Zuo Z, Qin X, Dong Y, Zhou Y, Qin H, Tao S, Du J, Liu J, Lu Z, Yin H, Mesquita A, Yuan CL, Hu YC, Sun W, Su R, Dong L, Shen C, Li C, Qing Y, Jiang X, Wu X, Sun M, Guan JL, Qu L, Wei M, Müschen M, Huang G, He C, Yang J, Chen J.

Nature. 2019 Mar;567(7748):414-419. doi: 10.1038/s41586-019-1016-7. Epub 2019 Mar 13.

11.

Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.

Mohanty A, Sandoval N, Phan A, Nguyen TV, Chen RW, Budde E, Mei M, Popplewell L, Pham LV, Kwak LW, Weisenburger DD, Rosen ST, Chan WC, Müschen M, Ngo VN.

Blood. 2019 Jan 24;133(4):306-318. doi: 10.1182/blood-2018-05-851667. Epub 2018 Dec 10.

PMID:
30530749
12.

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.

Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska-Wasowska K, Müschen M, Bhatia S, Bhatia R, Johnson N, Wasik MA, Mazin AV, Skorski T.

Cell Rep. 2018 Jun 12;23(11):3127-3136. doi: 10.1016/j.celrep.2018.05.034.

13.

Author Correction: Metabolic gatekeeper function of B-lymphoid transcription factors.

Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M.

Nature. 2018 Jun;558(7711):E5. doi: 10.1038/s41586-018-0164-5.

14.

B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.

Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, Jumaa H, Jiang X, Weinstock DM, Graeber TG, Müschen M.

Cell. 2018 Apr 5;173(2):470-484.e18. doi: 10.1016/j.cell.2018.02.048. Epub 2018 Mar 15.

15.

Loss of Pax5 Exploits Sca1-BCR-ABLp190 Susceptibility to Confer the Metabolic Shift Essential for pB-ALL.

Martín-Lorenzo A, Auer F, Chan LN, García-Ramírez I, González-Herrero I, Rodríguez-Hernández G, Bartenhagen C, Dugas M, Gombert M, Ginzel S, Blanco O, Orfao A, Alonso-López D, Rivas JL, García-Cenador MB, García-Criado FJ, Müschen M, Sánchez-García I, Borkhardt A, Vicente-Dueñas C, Hauer J.

Cancer Res. 2018 May 15;78(10):2669-2679. doi: 10.1158/0008-5472.CAN-17-3262. Epub 2018 Feb 28.

16.

CAMKs support development of acute myeloid leukemia.

Kang X, Cui C, Wang C, Wu G, Chen H, Lu Z, Chen X, Wang L, Huang J, Geng H, Zhao M, Chen Z, Müschen M, Wang HY, Zhang CC.

J Hematol Oncol. 2018 Feb 27;11(1):30. doi: 10.1186/s13045-018-0574-8.

17.

Highly multiplexed and quantitative cell-surface protein profiling using genetically barcoded antibodies.

Pollock SB, Hu A, Mou Y, Martinko AJ, Julien O, Hornsby M, Ploder L, Adams JJ, Geng H, Müschen M, Sidhu SS, Moffat J, Wells JA.

Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):2836-2841. doi: 10.1073/pnas.1721899115. Epub 2018 Feb 23.

18.

Autoimmunity checkpoints as therapeutic targets in B cell malignancies.

Müschen M.

Nat Rev Cancer. 2018 Feb;18(2):103-116. doi: 10.1038/nrc.2017.111. Epub 2018 Jan 5. Review.

PMID:
29302068
19.

Portending death in germinal centers - when B cells know their time is up.

Wang L, Müschen M.

Cell Res. 2018 Jan;28(1):5-6. doi: 10.1038/cr.2017.151. Epub 2017 Dec 1.

20.

Circadian clock cryptochrome proteins regulate autoimmunity.

Cao Q, Zhao X, Bai J, Gery S, Sun H, Lin DC, Chen Q, Chen Z, Mack L, Yang H, Deng R, Shi X, Chong LW, Cho H, Xie J, Li QZ, Müschen M, Atkins AR, Liddle C, Yu RT, Alkan S, Said JW, Zheng Y, Downes M, Evans RM, Koeffler HP.

Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12548-12553. doi: 10.1073/pnas.1619119114. Epub 2017 Nov 6.

21.

Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease.

Deng R, Hurtz C, Song Q, Yue C, Xiao G, Yu H, Wu X, Muschen M, Forman S, Martin PJ, Zeng D.

Nat Commun. 2017 Oct 17;8(1):978. doi: 10.1038/s41467-017-00880-2.

22.

Correction: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.

Sun H, Lin DC, Guo X, Masouleh BK, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koeffler HP.

Oncotarget. 2017 Sep 8;8(38):64651. doi: 10.18632/oncotarget.20707. eCollection 2017 Sep 8.

23.

Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia.

Takao S, Chien W, Madan V, Lin DC, Ding LW, Sun QY, Mayakonda A, Sudo M, Xu L, Chen Y, Jiang YY, Gery S, Lill M, Park E, Senapedis W, Baloglu E, Müschen M, Koeffler HP.

Leukemia. 2018 Mar;32(3):616-625. doi: 10.1038/leu.2017.281. Epub 2017 Sep 14.

PMID:
28904384
24.

Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia.

Gugliotta G, Sudo M, Cao Q, Lin DC, Sun H, Takao S, Le Moigne R, Rolfe M, Gery S, Müschen M, Cavo M, Koeffler HP.

Neoplasia. 2017 Oct;19(10):750-761. doi: 10.1016/j.neo.2017.08.001. Epub 2017 Aug 29.

25.

B-cell identity as a metabolic barrier against malignant transformation.

Chan LN, Müschen M.

Exp Hematol. 2017 Sep;53:1-6. doi: 10.1016/j.exphem.2017.06.004. Epub 2017 Jun 24. Review.

26.

Infection Exposure Promotes ETV6-RUNX1 Precursor B-cell Leukemia via Impaired H3K4 Demethylases.

Rodríguez-Hernández G, Hauer J, Martín-Lorenzo A, Schäfer D, Bartenhagen C, García-Ramírez I, Auer F, González-Herrero I, Ruiz-Roca L, Gombert M, Okpanyi V, Fischer U, Chen C, Dugas M, Bhatia S, Linka RM, Garcia-Suquia M, Rascón-Trincado MV, Garcia-Sanchez A, Blanco O, García-Cenador MB, García-Criado FJ, Cobaleda C, Alonso-López D, De Las Rivas J, Müschen M, Vicente-Dueñas C, Sánchez-García I, Borkhardt A.

Cancer Res. 2017 Aug 15;77(16):4365-4377. doi: 10.1158/0008-5472.CAN-17-0701. Epub 2017 Jun 19.

27.

mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL.

Vo TT, Lee JS, Nguyen D, Lui B, Pandori W, Khaw A, Mallya S, Lu M, Müschen M, Konopleva M, Fruman DA.

Mol Cancer Ther. 2017 Sep;16(9):1942-1953. doi: 10.1158/1535-7163.MCT-17-0024. Epub 2017 May 31.

28.

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T.

J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8.

29.

Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.

Kruth KA, Fang M, Shelton DN, Abu-Halawa O, Mahling R, Yang H, Weissman JS, Loh ML, Müschen M, Tasian SK, Bassik MC, Kampmann M, Pufall MA.

Blood. 2017 Jun 1;129(22):3000-3008. doi: 10.1182/blood-2017-02-766204. Epub 2017 Apr 19.

30.

Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.

Katerndahl CDS, Heltemes-Harris LM, Willette MJL, Henzler CM, Frietze S, Yang R, Schjerven H, Silverstein KAT, Ramsey LB, Hubbard G, Wells AD, Kuiper RP, Scheijen B, van Leeuwen FN, Müschen M, Kornblau SM, Farrar MA.

Nat Immunol. 2017 Jun;18(6):694-704. doi: 10.1038/ni.3716. Epub 2017 Apr 3.

31.

BCL6 promotes glioma and serves as a therapeutic target.

Xu L, Chen Y, Dutra-Clarke M, Mayakonda A, Hazawa M, Savinoff SE, Doan N, Said JW, Yong WH, Watkins A, Yang H, Ding LW, Jiang YY, Tyner JW, Ching J, Kovalik JP, Madan V, Chan SL, Müschen M, Breunig JJ, Lin DC, Koeffler HP.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3981-3986. doi: 10.1073/pnas.1609758114. Epub 2017 Mar 29. Erratum in: Proc Natl Acad Sci U S A. 2017 May 23;114(21):E4317.

32.

Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures.

Graham NA, Minasyan A, Lomova A, Cass A, Balanis NG, Friedman M, Chan S, Zhao S, Delgado A, Go J, Beck L, Hurtz C, Ng C, Qiao R, Ten Hoeve J, Palaskas N, Wu H, Müschen M, Multani AS, Port E, Larson SM, Schultz N, Braas D, Christofk HR, Mellinghoff IK, Graeber TG.

Mol Syst Biol. 2017 Feb 15;13(2):914. doi: 10.15252/msb.20167159.

33.

Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors.

Boulianne B, Robinson ME, May PC, Castellano L, Blighe K, Thomas J, Reid A, Müschen M, Apperley JF, Stebbing J, Feldhahn N.

Cell Rep. 2017 Feb 14;18(7):1687-1698. doi: 10.1016/j.celrep.2017.01.057.

34.

Metabolic gatekeeper function of B-lymphoid transcription factors.

Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M.

Nature. 2017 Feb 23;542(7642):479-483. doi: 10.1038/nature21076. Epub 2017 Feb 13. Erratum in: Nature. 2018 Jun;558(7711):E5.

35.

Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre-B ALL.

Schjerven H, Ayongaba EF, Aghajanirefah A, McLaughlin J, Cheng D, Geng H, Boyd JR, Eggesbø LM, Lindeman I, Heath JL, Park E, Witte ON, Smale ST, Frietze S, Müschen M.

J Exp Med. 2017 Mar 6;214(3):793-814. doi: 10.1084/jem.20160049. Epub 2017 Feb 11.

36.

Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.

Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, Müschen M, Davis RE, Burger JA.

Blood. 2017 Mar 2;129(9):1155-1165. doi: 10.1182/blood-2016-06-722900. Epub 2016 Dec 28.

37.

Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.

McCracken AN, McMonigle RJ, Tessier J, Fransson R, Perryman MS, Chen B, Keebaugh A, Selwan E, Barr SA, Kim SM, Roy SG, Liu G, Fallegger D, Sernissi L, Brandt C, Moitessier N, Snider AJ, Clare S, Müschen M, Huwiler A, Kleinman MT, Hanessian S, Edinger AL.

Leukemia. 2017 Mar;31(3):669-677. doi: 10.1038/leu.2016.244. Epub 2016 Aug 30.

38.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. No abstract available.

39.

Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia.

Randhawa S, Cho BS, Ghosh D, Sivina M, Koehrer S, Müschen M, Peled A, Davis RE, Konopleva M, Burger JA.

Br J Haematol. 2016 Aug;174(3):425-36. doi: 10.1111/bjh.14075. Epub 2016 Apr 12.

40.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Apr 11;29(4):574-586. doi: 10.1016/j.ccell.2016.03.008. Erratum in: Cancer Cell. 2016 Jul 11;30(1):183.

41.

PTEN opposes negative selection and enables oncogenic transformation of pre-B cells.

Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, Müschen M.

Nat Med. 2016 Apr;22(4):379-87. doi: 10.1038/nm.4062. Epub 2016 Mar 14.

42.

Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.

Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M.

Nature. 2016 Jun 2;534(7605):138. doi: 10.1038/nature16997. Epub 2016 Mar 9. No abstract available.

PMID:
26958840
43.

Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.

Sun H, Lin DC, Guo X, Kharabi Masouleh B, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koeffler HP.

Oncotarget. 2016 Apr 5;7(14):18736-49. doi: 10.18632/oncotarget.7702. Erratum in: Oncotarget. 2017 Sep 8;8(38):64651.

44.

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T.

Blood. 2016 Apr 28;127(17):2131-43. doi: 10.1182/blood-2015-11-681171. Epub 2016 Feb 10.

45.

BCOR regulates myeloid cell proliferation and differentiation.

Cao Q, Gearhart MD, Gery S, Shojaee S, Yang H, Sun H, Lin DC, Bai JW, Mead M, Zhao Z, Chen Q, Chien WW, Alkan S, Alpermann T, Haferlach T, Müschen M, Bardwell VJ, Koeffler HP.

Leukemia. 2016 May;30(5):1155-65. doi: 10.1038/leu.2016.2. Epub 2016 Feb 5.

46.

Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.

Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis RE, Burger JA.

Leukemia. 2016 Jun;30(6):1246-54. doi: 10.1038/leu.2016.9. Epub 2016 Feb 5.

47.

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.

Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M.

Cell Rep. 2015 Dec 29;13(12):2715-27. doi: 10.1016/j.celrep.2015.12.003. Epub 2015 Dec 17.

48.

Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia.

Song C, Pan X, Ge Z, Gowda C, Ding Y, Li H, Li Z, Yochum G, Muschen M, Li Q, Payne KJ, Dovat S.

Leukemia. 2016 Jun;30(6):1436-40. doi: 10.1038/leu.2015.331. Epub 2015 Dec 7. No abstract available.

49.

Infection and the Perils of B-cell Activation.

Greaves M, Müschen M.

Cancer Discov. 2015 Dec;5(12):1244-6. doi: 10.1158/2159-8290.CD-15-1243.

50.

MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.

Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP, Teachey DT, Raetz EA, Hermiston ML, Müschen M, Loh ML, Hunger SP, Zhang J, Garabedian MJ, Porter CC, Carroll WL.

Blood. 2015 Nov 5;126(19):2202-12. doi: 10.1182/blood-2015-04-639138. Epub 2015 Aug 31.

Supplemental Content

Loading ...
Support Center